References
- American Psychiatric Association, American Psychiatric Association. DSM-5 task force. Diagnostic and statistical manual of mental disorders: DSM-5. Washington (DC): American Psychiatric Association; 2013.
- DeBattista C, Glick ID. Pharmacotherapy of personality disorders. Curr Opin Psychiatry. 1995;8:102–105.
- Paton C, Crawford MJ, Bhatti SF, et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512–518.
- Volkert J, Gablonski T-C, Rabung S. Prevalence of personality disorders in the general adult population in Western countries: systematic review and meta-analysis. Br J Psychiatry. 2018;213:709–715.
- Stoffers-Winterling J, Storebø OJ, Lieb K. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep. 2020;22:37. .
- Crawford M, Sanatinia R, Barrett B, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018;175:756‐764.
- Bridler R, Haberle A, Muller ST, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25:763–772.
- Khalifa NR, Gibbon S, Völlm BA, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev. 2020;9:CD007667.
- 2018 surveillance of personality disorders (NICE guidelines CG77 and CG78). Surveillance report. NICE National Institute for Health and Care Excellence; 19 July 2018 [cited 2020 Dec 30. Available from: www.nice.org.uk/guidance/cg78/resources/2018-surveillance-of-personality-disorders-nice-guidelines-cg77-and-cg78-4906490080/chapter/Surveillance-decision?tab=evidence.2018
- Jakobsen KD, Skyum E, Hashemi N, et al. Antipsychotic treatment of schizotypy and schizotypal personality disorder: A systematic review. J Psychopharmacol. 2017;31:397–405.
- Harvey PD, Jones MT. Functional deficits in attenuated psychosis syndrome and related conditions: current and future treatment options. Schizophr Res Cogn. 2019;17:100152.
- Paris J. Why patients with severe personality disorders are overmedicated. J Clin Psychiatry. 2015;76:e521.
- Hutsebaut J, Willemsen E, Bachrach N, et al. Improving access to and effectiveness of mental health care for personality disorders: the guideline-informed treatment for personality disorders (GIT-PD) initiative in the Netherlands. Borderline Personal Disord Emot Dysregul. 2020;7:16.
- Vita AL, De Peri L, Sacchetti E. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials. J Clin Psychopharmacol. 2011;31:613–624.
- ICD-11 - Mortality and morbidity statistics [Internet]. [cited 2020 Nov 12]. Available from: https://icd.who.int/en.
- Storebø OJ, Stoffers-Winterling JM, Völlm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020;5:CD012955.